In summary, our findings revealed that genistein, a tyrosine kinase inhibitor, inhibits EGFR expression, resulting in the restriction of the Akt and JAK1/2 signaling pathways, thereby suppressing cell proliferation and inducing tumor cell apoptosis in vitro and in vivo. The gene discussed is JAK1; the disease is neoplasm.